Results for
"[search-keyword]"
Sponsor content
1087 result(s) found, displaying 1 to 10
-
Australian Public Assessment Report (AusPAR)Jubbonti, a biosimilar to Prolia, and Wyost, a biosimilar to Xgeva (both denosumab), have been approved to improve bone density and to reduce bone fracture risk as a consequence of disease or medications that weaken bones.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for APIXABAN SANDOZ apixaban 5 mg film-coated tablet blister pack.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for APIXABAN SANDOZ apixaban 2.5 mg film-coated tablet blister pack.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for JUBBONTI denosumab 60mg/1mL solution for injection prefilled syringe with automatic needle guard.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for WYOST denosumab 70mg/mL (120mg/1.7mL) solution for injection vial.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for DABIGATRAN SANDOZ dabigatran etexilate (as mesilate) 150 mg capsule bottle.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for DABIGATRAN SANDOZ dabigatran etexilate (as mesilate) 110 mg capsule bottle.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for DABIGATRAN SANDOZ dabigatran etexilate (as mesilate) 75 mg capsule bottle.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for DULOXETINE SANDOZ duloxetine (as hydrochloride) 60 mg enteric capsule blister pack.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for DULOXETINE SANDOZ duloxetine (as hydrochloride) 30 mg enteric capsule blister pack.